Bilateral subcutaneous synergic mouse tumour model with single-sided intra-tumoural OV injection:Disease control: significantly decreased tumour growth in both injected and non-injected tumours and greater long-term tumour growth inhibition compared to parental OV and untreated; successful tumour rejection upon rechallengeImmune response: significantly increased activated CD4+ and CD8+ cell tumour infiltration compared to parental OV; however, also saw significantly greater MDSC infiltration compared to parental OV. This evidence concerns the gene CD4 and neoplasm.